The landscape of obesity treatment in the United Kingdom is on the cusp of significant transformation with the upcoming introduction of a new generation of GLP-1 based medications. These drugs, initially developed for diabetes over two decades ago, have recently gained traction as potent appetite suppressants and weight-loss aids. This evolution has led to the relicensing and rebranding of existing medications and the development of novel compounds, promising a more accessible and diverse treatment ecosystem.
The most immediate development is the approval of the Wegovy Pill, an oral, once-daily formulation of the injectable Wegovy. This new option, containing the active ingredient semaglutide, mimics a gut hormone that reduces appetite, leading to decreased calorie intake and subsequent weight loss. While clinical trials indicate a slightly lower efficacy compared to the injectable form – with participants losing approximately 17% of their body weight versus up to 20.7% with the jab – it offers a more convenient daily regimen. The pill is expected to be available privately from early July, with a starting dose of 1.5mg and a maximum of 25mg, though those on the weekly injection can switch directly to the higher tablet dose. Its approval by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) follows greenlights in the US and the United Arab Emirates, making the UK the first European nation to approve it. It is currently indicated for private prescription for individuals with a BMI over 30, or a BMI between 27 and 30 with a weight-related medical condition.
Looking ahead, orforglipron, a rival pill developed by Eli Lilly, is anticipated later this year. Clinical trials involving patients with type 2 diabetes have shown promising results, with both 12mg and 36mg doses demonstrating superior reductions in blood sugar levels and greater weight loss compared to oral semaglutide. Notably, up to 43% of participants on orforglipron achieved at least a 10% body weight reduction, a significant figure for managing type 2 diabetes and its associated risks. Orforglipron also offers the convenience of being taken with food, unlike semaglutide. The drug received US approval in April, with a decision for UK use expected before the year's end.
Further advancements include retatrutide, a compound that targets three hormones: GLP-1, GIP, and glucagon. This 'GLP-3' drug has shown remarkable results in trials. In a study with type 2 diabetes patients, it led to an average weight loss of 15.3% (approximately 33lbs) and significant improvements in blood sugar control. An obesity trial without diabetes patients reported an even more substantial average weight loss of 24.2% (about 52 pounds) on a 12mg dose. The multi-receptor targeting mechanism of retatrutide may promote increased energy expenditure and fat burning. While retatrutide is still in the trial phase and not yet authorized globally, regulatory applications are anticipated once final studies are completed.
China is also contributing to the development with mazdutide, a weekly injection that targets GLP-1 and glucagon receptors. Phase three trials in Chinese adults with obesity showed an average weight loss of 16.7% after 60 weeks. The drug also demonstrated broader health benefits, including improvements in blood sugar, cholesterol, waist circumference, and blood pressure. Mazdutide has received approval in China, with submissions for regulatory approval in Britain, the US, and Europe expected in the future.
These emerging treatments represent a significant step forward in managing obesity and related chronic conditions. Experts suggest that the increased accessibility and diversity of these medications could be transformative for public health, offering tangible benefits to individuals and society at large. Abdal Alvi, chief clinical officer at Simple Online Healthcare, described the current moment as "genuinely exciting" for obesity medicine, highlighting the potential for a "genuinely transformative" impact on the UK's health future.